Author: Kira, Hitomi ; Utoguchi, Naoki ; Iino, Hayato ; Hashizaki, Kaname ; Fujino, Manami ; Fujii, Makiko ; Kohara, Shizuka ; Koizumi, Naoya ; Watanabe, Yoshiteru

Skin penetration amounts of a highly lipophilic drug, ufenamate, prepared in four oily vehicles, including white petrolatum (WP), liquid paraffin (LP), isopropyl myristate (IPM), and isocetyl stearate (ICS), were compared. Ufenamate was mixed in each vehicle at 5% and applied at a rate of 2 mg/cm² to intact, stripped, and delipidized Yucatan micropig skin. The amounts of ufenamate and IPM in the stratum corneum (SC), epidermis, and dermis were determined. The skin penetration amounts of ufenamate from liquid oils were significantly higher than those from WP; the amounts of ufenamate were in the order WP

01 Jan 2015·Biological & Pharmaceutical BulletinQ4 · MEDICINE

Penetration of Ufenamate into Intact, Stripped, or Delipidized Skin Using Different Vehicles

Q4 · MEDICINE

Article

Author: Iino, Hayato ; Watanabe, Yoshiteru ; Fujii, Makiko ; Koizumi, Naoya ; Fujino, Manami

The purpose of this study was to clarify the effect of skin condition on skin penetration of the very high lipophilic drug, ufenamate (UF). UF was applied to stripped or delipidized skin using liquid paraffin (LP) or purified water containing polysorbate 80 at a dose of 2 µL/cm(2). We found that UF penetration into intact and stripped skin using a water vehicle was respectively 5 and 10 times higher than that using LP. UF is freely soluble in oil and insoluble in water; thus, activity in water is higher than that in LP. Therefore, it is useful to use a water-based vehicle for both intact sites and those with defective stratum corneum (SC). Conversely, we found that delipidization of SC decreased the penetration of UF significantly with both LP and water, and the amount measured in the epidermis was 1 µg/cm(2) with both vehicles. This indicates that UF is not suitable for so-called "dry skin." This study revealed clinically relevant differences in the penetration of UF into intact, stripped, or delipidized skin conditions.

01 Jun 2011·Journal of Drug TargetingQ3 · MEDICINE

Evaluation of dextran-flufenamic acid ester as a polymeric colon-specific prodrug of flufenamic acid, an anti-inflammatory drug, for chronotherapy

Q3 · MEDICINE

Article

Author: In Ho Kim ; Yunjin Jung ; Jeong Hyun Yoon ; Young Hee Shin ; Young Mi Kim ; Jeongyun Kim ; Yonghyun Lee

Dextran-flufenamic acid ester (Dex-FFA) with varied degree of substitution (DS) was prepared by imidazolide method. Dex-FFA was stable in pH 1.2 or pH 6.8 buffer. The depolymerization degree of Dex-FFA by dextranase decreased as DS increased. Dex-FFA with DS of 13 or 20 released FFA up to 70% or 21% of the dose, respectively, on 24 h-incubation with the 10% cecal contents. FFA was liberated up to 29% of the dose on 24 h-incubation of dextranase pre-treated Dex-FFA with the homogenates of the upper intestine, whereas no FFA was detected devoid of dextranse-pretreatment. Upon oral administration of Dex-FFA (DS 13, 20 mg equivalent of FFA/kg) or FFA (10 mg/kg) to rats, t(max) for FFA with Dex-FFA administration delayed approximately 6 h compared with that of free FFA administration, while C(max) for FFA was similar. The plasma level for FFA became greater around 6 h after administration of Dex-FFA than free FFA and it was maintained throughout the period of 24 h-experiment. Dex-FFA markedly attenuated gastric ulcerogenicity of FFA. Taken together, Dex-FFA could be useful as a colon-specific prodrug which possesses anti-inflammatory properties and offers opportunities as a chronotherapeutic approach for the treatment of arthritis.

100 Deals associated with Ufenamate

External Link

KEGG	Wiki	ATC	Drug Bank
D01823	Ufenamate	M01AG03	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute eczema	JP	Viatris Pharmaceutical LLC	01 Feb 1983
Chronic eczema	JP	Viatris Pharmaceutical LLC	01 Feb 1983
Dermatitis, Perioral	JP	Viatris Pharmaceutical LLC	01 Feb 1983
Rosacea-like dermatitis	JP	Viatris Pharmaceutical LLC	01 Feb 1983
Dermatitis, Atopic	JP	Mitsubishi Tanabe Pharma Corp.	07 Oct 1982
Dermatitis, Contact	JP	Mitsubishi Tanabe Pharma Corp.	07 Oct 1982
Dermatitis, Seborrheic	JP	Mitsubishi Tanabe Pharma Corp.	07 Oct 1982
Herpes Zoster	JP	Mitsubishi Tanabe Pharma Corp.	07 Oct 1982
Eczema	CN	Shenyang Antibiotic Factory	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis